R-Biopharm AG: Flu tests from R-Biopharm also detect new virus variants
Darmstadt, November 25, 2022: The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.
"Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."
This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.
R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/de/kontakt/presse
https://r-biopharm.com/de/news-presse/download-galerie
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Phone: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase9.5.2025 12:00:00 CEST | Press release
(Vienna, Austria) Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease. Biomay is the FDA-approved manufacturer of recombinant Cas9 as the essential component of CASGEVY®, the very first CRISPR genome editing product on the market. Biomay’s Cas9 (internal code “BMC9”) is based on the classical wild-type Cas9 nuclease from Streptococcus pyogenes. The Cas9 manufacturing process has been de novo developed, GMP-implemented and PPQ-validated by Biomay. GMP and RUO manufacturing is performed by fermentation with E. coli and by purification with chromatographic methods. By quality control with a comprehensive set of validated analytical assays, the consistent
mAInthink GmbH: Technological Breakthrough: Hallucination-Free Superintelligence Achieves 99.99% Strategic Accuracy – Germany Gains Permanent Strategic Superiority9.5.2025 10:57:00 CEST | Press release
Worms, May 9, 2025 – The mAInthink GmbH has achieved a technological breakthrough that redefines the future of strategic decision-making: With the development of StratePlan, a hallucination-free superintelligence delivering verified 99.99% strategic accuracy, Germany secures permanent technological, economic, and geopolitical superiority – operationally deployable and scientifically validated.
HEIDELBERG/Amperfied presents new DC fast charging solution with comprehensive range of services: Focus on dynamic power distribution and high availability7.5.2025 08:56:00 CEST | Press release
Offer is aimed at the increasing demand from charging parks, logistics depots and haulage fleets Amperfied addresses demand for fast charging system solutions with new DC product and performance-based offering DC becomes part of an availability-based operating hours model Modular technology for optimum utilization of the charging system and small footprint Debut at the Power2Drive 2025 Amperfied GmbH, a subsidiary of Heidelberger Druckmaschinen AG (HEIDELBERG), is entering the market for fast charging solutions complete with a comprehensive range of services. At the Power2Drive trade fair in Munich, the company will unveil its modular DC fast charging solution called Amperfied Dynamic DC, which focuses on availability and efficiency. The offering is aimed primarily at the growing demand from charging parks, logistics depots and haulage fleets for high-availability system solutions. This is because only with fast and functional charge points can charging infrastructure operators (CPOs)
HEIDELBERG holds its ground in a difficult market environment in FY 2024/25 - targets achieved, significant increase in incoming orders compared to previous year6.5.2025 08:52:59 CEST | Press release
Sales and adjusted EBITDA margin at previous year's level according to preliminary figures Free cash flow excluding special items clearly positive at around € 50 million Rising order intake compared to previous year lays the foundation for a good start to FY 2025/26 Additional, positive order impetus expected from China Print trade fair in May Adjusted EBITDA margin to rise to around 8 percent in FY 2025/26
eM Client version 10.3 adds features familiar from Postbox5.5.2025 13:32:56 CEST | Press release
Prague – 05.05.2025 - The Czech company eM Client has launched a new version of its eponymous email application, positioning their software as the primary rival to Microsoft Outlook in the email app market. The most recent release, version 10.3, also incorporates the most popular features from Postbox, an email application developed by Postbox Inc., which has ceased operations and was acquired by eM Client in 2024.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom